| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-92 |
Sentence |
denotes |
Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs |
| T2 |
93-120 |
Sentence |
denotes |
FcγR and mAb immune therapy |
| T3 |
121-140 |
Sentence |
denotes |
AM Chenoweth et al. |
| T4 |
142-150 |
Sentence |
denotes |
Abstract |
| T5 |
151-159 |
Sentence |
denotes |
Abstract |
| T6 |
160-447 |
Sentence |
denotes |
The human fragment crystallizable (Fc)γ receptor (R) interacts with antigen‐complexed immunoglobulin (Ig)G ligands to both activate and modulate a powerful network of inflammatory host‐protective effector functions that are key to the normal physiology of immune resistance to pathogens. |
| T7 |
448-633 |
Sentence |
denotes |
More than 100 therapeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. |
